Compounds > deferasirox
Page last updated: 2024-09-05

deferasirox and cyclin d1

deferasirox has been researched along with cyclin d1 in 3 studies

Compound Research Comparison

Studies
(deferasirox)		Trials
(deferasirox)		Recent Studies (post-2010)
(deferasirox)		Studies
(cyclin d1)		Trials
(cyclin d1)		Recent Studies (post-2010) (cyclin d1)
83213657210,885705,157

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Dreyling, M; Granot, G; Levi, I; Mor-Tzuntz, R; Nathan, I; Shpilberg, O; Vazana-Barad, L1
Ford, SJ; Jansson, PJ; Kalinowski, DS; Kovacevic, Z; Lovejoy, DB; Lui, GY; Obeidy, P; Richardson, DR; Sharp, DM; Tselepis, C1
Avigad, S; Granot, G; Lubin, I; Raanani, P; Samara, A; Shapira, S; Shpilberg, O1

Other Studies

3 other study(ies) available for deferasirox and cyclin d1

ArticleYear
Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Benzoates; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclin D1; Deferasirox; Gene Expression Regulation, Neoplastic; Humans; Iron; Iron Chelating Agents; Lymphoma, Mantle-Cell; Proteasome Endopeptidase Complex; Proteolysis; RNA, Messenger; Triazoles

2013
The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
    Molecular pharmacology, 2013, Volume: 83, Issue:1

    Topics: Administration, Oral; Animals; Antigens, CD; Antineoplastic Agents; Apoptosis; Benzoates; Cell Cycle; Cell Line, Tumor; Copper; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Deferasirox; Female; Humans; Iron; Iron Chelating Agents; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neuroectodermal Tumors, Primitive, Peripheral; Protein Serine-Threonine Kinases; Receptors, Transferrin; Small Cell Lung Carcinoma; Transplantation, Heterologous; Triazoles; Zinc

2013
Deferasirox induces cyclin D1 degradation and apoptosis in mantle cell lymphoma in a reactive oxygen species- and GSK3β-dependent mechanism.
    British journal of haematology, 2021, Volume: 192, Issue:4

    Topics: Apoptosis; Cell Line, Tumor; Cyclin D1; Deferasirox; Glycogen Synthase Kinase 3 beta; Humans; Iron Chelating Agents; Lymphoma, Mantle-Cell; Proteolysis; Reactive Oxygen Species; Tumor Cells, Cultured

2021